UNSPSC 51271625: Butanilicaine phosphate

This classification denotes an anesthetic agent with the molecular formula C13H19CLN2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JOZ20TRV0N. European Medicines Agency schedules butanilicaine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00912MIG. The term butanilicaine phosphate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule butanilicaine phosphate under HS 29242995 and SITC 51479.

As of Q4 2014, BUTANILICAINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Butanilicaine phosphate bears US NLM identifiers UMLS ID C0888854 and NCI Concept Code C97305. SMILES: CCCCNCC(=O)NC1C(CCCC1CL)C.OP(=O)(O)O.

UNSPSC 51271625 Butanilicaine phosphate is a Commodity code representing a specific pharmaceutical active ingredient that state and local governments procure as part of broader generic pharmaceutical supply agreements. The code appears in practice within multi-source pharmaceutical procurement frameworks where state agencies and their purchasing cooperatives source finished pharmaceutical products and active pharmaceutical ingredients through established wholesaler networks. Solicitations under this code reflect institutional healthcare needs across state departments, county health systems, municipal clinics, and other public health facilities that depend on reliable generic drug supplies at competitive pricing.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products serving participating state and local government facilities across Minnesota and Oregon. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and provide detailed product specifications including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing locations. Award evaluation weights price competitiveness at 75 percent, with the remainder split among fixed pricing, administrative compliance, EDI capability, and a required 3 percent administrative fee structure. Vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three authorized wholesalers with chargeback systems in place, and carry commercial general liability insurance of $5 million per occurrence. The contract term runs two years with optional extensions, and awarded vendors will be effective July 1, 2026, with performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.